NICE to Charge up to $282,000 for New Drug Assessments

The UK’s National Institute of Health and Care Excellence (NICE) plans to start charging pharmaceutical companies new fees for each cost-effectiveness assessment for a new medicine beginning next year. The new fees could be up to $282,000! Find out more here. (Source: Zachary Brennan, RAPS, 10/3/16)

You might also be interested in:

Scientist.com to Acquire HealthEconomics.Com, the World’s… 12/15/2020
What Are The Recent Top 4 Innovative Consolidations and… 08/26/2020
EQRx Scales Disruptive Model of Important New Medicines 01/11/2021
Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
Matthew McHugh Appointed Director for Health Outcomes and… 02/10/2021
Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020
Are Healthcare Prices in the U.S. Too High, Too Low, or Both? 08/25/2020